Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
biotechdaily.com
Drug Discovery
Features Subscription Partner Sites Journal Info
PZ HTL SAGLOBETECH PUBLISHING

Interferon Treatment Eradicates a New Human Coronavirus in a Culture Model

By BiotechDaily International staff writers
Posted on 06 Mar 2013


A recently recognized human coronavirus was treated successfully in an in vitro model based on human bronchial epithelial tissue, which reduces fears that the virus might be capable of setting off a worldwide respiratory disease pandemic.

The recent emergence of a novel human coronavirus (HCoV-EMC) in the Middle East raised considerable concerns, as it was found to be associated with severe acute pneumonia, renal failure, and fatal outcome and thus resembled the clinical presentation of severe acute respiratory syndrome (SARS) observed in 2002 and 2003. Like SARS-CoV, HCoV-EMC is of zoonotic origin and closely related to bat coronaviruses.

To get a handle on this potentially fatal pathogen, investigators at Kantonal Hospital (St. Gallen, Switzerland) developed an in vitro model based on human bronchial epithelial cells, which are highly susceptible to HCoV-EMC infection and in which the virus is able to multiply at a faster initial rate than the SARS virus. The investigators employed advanced genomic research tools such as reverse transcription (RT)-PCR and RNAseq data to experimentally determine the identity of seven HCoV-EMC subgenomic mRNAs.

Results published in the February 19, 2013, online edition of the journal mBio revealed that while the human bronchial epithelial cells were readily responsive to type I and type III interferon (IFN), neither a pronounced inflammatory cytokine nor any detectable IFN responses were found following HCoV-EMC infection, suggesting that innate immune evasion mechanisms and possible IFN antagonists of the virus were operational in the human host. On the other hand, type I and type III IFN were found to efficiently reduce HCoV-EMC replication in the human cell cultures, providing a possible treatment option in cases of suspected HCoV-EMC infection.

"Surprisingly, this coronavirus grows very efficiently on human epithelial cells," said senior author Dr. Volker Thiel, a senior research fellow at Kantonal Hospital. "The other thing we found is that the viruses (HCoV-EMC, SARS, and the common cold virus) are all similar in terms of host responses: they do not provoke a huge innate immune response. We do not know whether the cases we observe are the tip of the iceberg, or whether many more people are infected without showing severe symptoms."

Related Links:
Kantonal Hospital





Laboratory Balance
Laboratory Balance
Standard Probes
Standard Probes
Liquid Handling System
Liquid Handling System

More Products

Latest Drug Discovery News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Whitepaper
Veolia WATER:
Why pure water is important in modern chromatography

Download Whitepaper
Featured Video
BioTek:

View Video
Events
The 23rd Annual Scientific Meeting
09 Jul 2013 - 10 Jul 2013


27th Annual Symposium of the Protein Society
20 Jul 2013 - 24 Jul 2013


AACC 2013 – Annual Meeting of the American Association for Clinical Chemistry
28 Jul 2013 - 01 Aug 2013


More events
Latest Issue

View Digital Edition
Subscribe / Renew
GLOBETECH PUBLISHING'
PZ HTL SA
VISION-SCIENCES, INC.
  biotechdaily.com Copyright © 2000-2013 Globetech Media. All rights reserved.
Privacy Policy